This company focuses on natural-origin, high-potency, cytotoxic and niche APIs, operating R&D and production platforms for new salt and crystal forms while cooperating deeply with clients on IND, NDA, ANDA and 505(b)(2)/P-IV challenge filings. It also explores the potential of macromolecular APIs through R&D and production platforms for glycans and polypeptides, specializes in XDC drugs with platforms for payload and linker innovation, and offers API CMO/CDMO services backed by a globalized registration platform, professional team and international cGMP system.

No comments available.
Leave your rating & comment